Health Economics›T-cell acute lymphoblastic leukemia›Upfront induction therapy

Upfront induction therapy

T-cell acute lymphoblastic leukemia · 2 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Cyclophosphamide, Daunorubicin, L-Asparaginase, Vincristine, Prednisone Variant #04 Partial	—	R 29 539	28d	—	—	~1	~R 29 539 indirect	—
Daunorubicin, Pegaspargase, Vincristine, Dexamethasone Variant #01 Partial	—	R 12 738	28d	—	—	~1	~R 12 738 indirect	—

2 of 2 regimens shown